検索結果 - David D. Stenehjem

  • 検索結果 1 - 8 結果 / 8
結果の絞り込み
  1. 1
    Panobinostat for the treatment of multiple myeloma: the evidence to date

    Panobinostat for the treatment of multiple myeloma: the evidence to date 著者: Sunil Sharma, Hanna Bailey, David D. Stenehjem

    出版事項 2015
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer 著者: David D. Stenehjem, Dao Tran, Michael Nkrumah, Shilpa Gupta

    出版事項 2018
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  3. 3
    Tumor mutational burden in lung cancer: a systematic literature review

    Tumor mutational burden in lung cancer: a systematic literature review 著者: Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Zyczynski, Diana Brixner, David D. Stenehjem

    出版事項 2019
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  4. 4
    Cancer incidence in immunocompromised patients: a single-center cohort study

    Cancer incidence in immunocompromised patients: a single-center cohort study 著者: Sabrina Ilham, Connor Willis, Kibum Kim, Karen Chung, Brenda Wood, Malinda S. Tan, Chia Jie Tan, Danielle Nguyen, Diana Brixner, David D. Stenehjem

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer 著者: David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma 著者: James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal

    出版事項 2017
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy

    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy 著者: Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild

    出版事項 2020
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer 著者: Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: